System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ppublish 3 citations

PubMed: 39351795 DOI: 10.1093/neuonc/noae200

Do we need dosimetry for the optimization of theranostics in CNS tumors?

Neuro Oncol 26(Supplement_9):S242-S258

Authors: Francesco Cicone, Silvano Gnesin, Giulia Santo, Caroline Stokke, Mirco Bartolomei, Giuseppe Lucio Cascini, Giuseppe Minniti, Giovanni Paganelli, Antoine Verger, Marta Cremonesi

Affiliations

  • Nuclear Medicine Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
  • Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Department of Physics, University of Oslo, Oslo, Norway.
  • Department of Diagnostic Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
  • Nuclear Medicine Unit, Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
  • IRCCS Neuromed, Pozzilli (IS), Italy.
  • Radiation Oncology Unit, Department of Radiological Sciences, Oncology and Anatomical Pathology, "Sapienza" University of Rome, Rome, Italy.
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.
  • Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU-Nancy, IADI, INSERM, UMR 1254, Université de Lorraine, Nancy, France.
  • Unit of Radiation Research, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Abstract

Radiopharmaceutical theranostic treatments have grown exponentially worldwide, and internal dosimetry has attracted attention and resources. Despite some similarities with chemotherapy, radiopharmaceutical treatments are essentially radiotherapy treatments, as the release of radiation into tissues is the determinant of the observed clinical effects. Therefore, absorbed dose calculations are key to explaining dose-effect correlations and individualizing radiopharmaceutical treatments. The present article introduces the basic principles of internal dosimetry and provides an overview of available loco-regional and systemic radiopharmaceutical treatments for central nervous system (CNS) tumors. The specific characteristics of dosimetry as applied to these treatments are highlighted, along with their limitations and most relevant results. Dosimetry is performed with higher precision and better reproducibility than in the past, and dosimetric data should be systematically collected, as treatment planning and verification may help exploit the full potential of theranostic of CNS tumors.

MeSH

Brain Neoplasms, Neoplasms, Radiopharmaceuticals, Therapeutics

Cited by